Marinus H. J. van Oers

Author

Amsterdam UMC Location University of Amsterdam

Also Known As

M H J Van Oers, M H J van Oers, M H Van Oers, M H van Oers, M. H. J. VAN OERS, M. H. J. Van Oers, M. H. J. van Oers, M. H.J. Van Oers, M. H.J. van Oers, M.H. J. van Oers

279

Publications

12.7K

Citations

H-Index

130

Concepts

All Affiliations

Amsterdam UMC Location University of Amsterdam University of Amsterdam Sanquin The Netherlands Cancer Institute Erasmus MC

About

Marinus H. J. van Oers is an author at Amsterdam UMC Location University of Amsterdam specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	46	3.2K
2	Health Sciences	5	5	263
3	Natural Sciences	2	2	108
4	Public Health	2	2	79
5	Nursing	1	1	21

Marinus H. J. van Oers

124

Publications

11.4K

Citations

H-Index

Page 1

	Year	Citations
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial Marinus H. J. van Oers, Richard Klasa, Robert Marcus, Blood	2006	592
Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma Franck Morschhauser, John Radford, Achiel Van Hoof, Journal of Clinical Oncology	2008	458
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study Bertrand Coiffier, Stéphane Leprêtre, Lars Møller Pedersen, Blood	2007	383
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study Marinus H. J. van Oers, M. van Glabbeke, L. Giurgea, Journal of Clinical Oncology	2010	336
Complement activation plays a key role in the side‐effects of rituximab treatment Lizet E. van der Kolk, A.J. Grillo-López, Joke W. Baars, British Journal of Haematology Key RoleImmunologyPathologyPharmacotherapyImmunotherapy	2001	322
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells Patrick W.B. Derksen, Esther P.M. Tjin, Helen P. Meijer, Proceedings of the National Academy of Sciences	2004	301
A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe Joppe W. Hovius, Bob de Wever, Maaike Söhne, The Lancet Parasitic DiseasePathogenesisTick-borne DiseaseDisease OutbreakEmerging Infectious Disease	2013	290
Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome H M Lokhorst, A Schattenberg, Jan J. Cornelissen, Journal of Clinical Oncology	2000	287
Rituximab treatment results in impaired secondary humoral immune responsiveness Lizet E. van der Kolk, Joke W. Baars, Martin H. Prins, Blood	2002	278
miR-34a as part of the resistance network in chronic lymphocytic leukemia Thorsten Zenz, Julia Mohr, Eric Eldering, Blood	2008	277

Page 1